dc.contributor.author | Valan, Christine Damgaard | |
dc.contributor.author | Slagsvold, Jens Erik | |
dc.contributor.author | Halvorsen, Tarje Onsøien | |
dc.contributor.author | Herje, Martin | |
dc.contributor.author | Bremnes, Roy M. | |
dc.contributor.author | Brunsvig, Paal Fr. | |
dc.contributor.author | Brustugun, Odd Terje | |
dc.contributor.author | Fløtten, Øystein | |
dc.contributor.author | Levin, Nina | |
dc.contributor.author | Sundstrøm, Stein Harald | |
dc.contributor.author | Grønberg, Bjørn Henning | |
dc.date.accessioned | 2018-10-12T10:40:52Z | |
dc.date.available | 2018-10-12T10:40:52Z | |
dc.date.issued | 2018-02 | |
dc.description.abstract | Background/Aim: <br>There are several definitions of
limited disease (LD) in small cell lung cancer (SCLC),
differing with respect to N3 disease accepted. We analyzed
patients from a randomized trial comparing two schedules of
thoracic radiotherapy (TRT) in LD SCLC to investigate
whether there were survival differences between N3
subcategories (n=144). Patients and <br>Methods: <br>Patients with
a baseline CT scan available were analysed. Patients received
four courses of cisplatin/etoposide and TRT of 45 Gy/30
fractions (twice daily) or 42 Gy/15 fractions (once daily).<br>
Results: <br>Median overall survival (OS) was 23.3 months in the
whole cohort. N3-patients (n=37) had shorter survival than
those with N0-2 (16.7 vs. 33.0 months; p<0.001). There were
no significant OS-differences between the N3 subcategories,
but patients with metastases to two or more N3 regions had
shorter survival than other N3 patients (13.4 vs. 19.9 months;
p=0.011). <br>Conclusion: <br>There were no survival differences
between the N3 subcategories, suggesting that all N3 disease
should be considered as LD. | en_US |
dc.description.sponsorship | The Central Norway Regional Health Authority (RHA),
The Norwegian University of Science and Technology (NTNU)
The Norwegian Cancer Society. | en_US |
dc.description | Source at: <a href=http://doi.org/10.21873/anticanres.12296> http://doi.org/10.21873/anticanres.12296</a> | en_US |
dc.identifier.citation | Valan, C. D., Slagsvold, J. E., Halvorsen, T., Herje, M., Bremnes, R. M., Brunsvig, P. F., ... Grønberg, B. H. (2018). Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement. Anticancer Research, 38(2), 871-876. http://doi.org/10.21873/anticanres.12296 | en_US |
dc.identifier.cristinID | FRIDAID 1545898 | |
dc.identifier.issn | 0250-7005 | |
dc.identifier.issn | 1791-7530 | |
dc.identifier.uri | https://hdl.handle.net/10037/13952 | |
dc.language.iso | eng | en_US |
dc.publisher | International Institute of Anticancer Research | en_US |
dc.relation.journal | Anticancer Research | |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 | en_US |
dc.title | Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |